Mazdutide 10mg 

Product Information and Research Background

Mazdutide 10mg is a product listing name referring to a stated 10 mg quantity of mazdutide, a peptide-based compound studied for its activity at the glucagon-like peptide-1 (GLP-1) and glucagon receptors. For Peptide Depot, the brand, physical format, packaging, manufacturer, purity, batch documentation and precise product classification have not been provided. These details must be verified before the page is published as a purchasable product.

Mazdutide is also known in scientific literature as IBI362 and LY3305677. Researchers have investigated its dual-receptor activity in clinical studies. However, findings from clinical trials of a specific investigational or authorised medicinal product do not establish the identity, quality, safety or suitability of a separate item labelled “Mazdutide 10mg”.

Important UK regulatory consideration: Mazdutide received approval for commercialisation in China in 2025, according to a report from the Shanghai municipal government. That does not establish authorisation for sale in the United Kingdom. Before offering this product to UK customers, Peptide Depot must verify the exact product’s legal classification, applicable authorisations and permitted supply route. The MHRA explains the requirements relating to the supply of unlicensed medicines in its official guidance on unlicensed medicinal products.

Shanghai Government

+1

Product overview

Mazdutide is a dual agonist of GLP-1 and glucagon receptors. These receptors are involved in metabolic signalling, making the compound relevant to scientific investigations of energy regulation and metabolic physiology.

The name Mazdutide 10mg describes the stated product strength or quantity, but the exact meaning of that figure depends on the verified product specification. It should not be assumed to mean 10 mg of analytically confirmed active ingredient without supporting documentation.

At present, the brand and category have not been supplied, and the available information does not confirm whether the item is a vial, powder, solution or another presentation. Photographs, label details, packaging contents, storage conditions and batch-specific documents should be checked against the actual item rather than inferred from other mazdutide products.

Why choose this product listing?

A reliable product page should help visitors distinguish a product’s stated identity from information that has been independently verified. For Mazdutide 10mg, that means clearly displaying the manufacturer or supplier identity, the precise quantity basis, physical format and any documentation genuinely available for the specific batch.

Where applicable, product documentation may include a batch or lot number, a Certificate of Analysis (CoA), analytical methods and the identity of the testing laboratory. These documents should only be described as available when they have actually been obtained and checked. A generic certificate or a document for a different batch is not evidence of the quality of the item being offered.

Likewise, clear photographs can help customers understand the physical presentation, but an image alone cannot establish chemical identity, purity, sterility or regulatory status. Transparent specifications are more useful than unsupported descriptions such as “pharmaceutical grade”, “ultra-pure” or “clinically proven”.

For Peptide Depot, the strongest approach is to provide accurate, product-specific information and disclose any limitations in the available evidence.

Research information: what is mazdutide?

Mazdutide is a peptide-based dual agonist targeting the GLP-1 and glucagon receptors. It has been investigated in clinical research involving adults with overweight or obesity and in studies involving type 2 diabetes. These trials assess the effects and tolerability of defined study formulations under controlled conditions; they do not validate the contents of an unrelated product sold under the same name.

A published Phase 1b study examined mazdutide, also identified as IBI362, at doses including 10mg in Chinese adults with overweight or obesity. The researchers assessed safety, tolerability and changes in several clinical measures. The paper is available through PubMed Central. Its findings belong to the studied formulation and trial conditions and should not be interpreted as a guarantee of results from another product.

PubMed

Other peer-reviewed studies have investigated mazdutide at different doses and in different study populations. For example, a Phase 2 trial published in Nature Communications examined mazdutide in Chinese adults with overweight or obesity. Readers can consult the original paper through PubMed to review its methods, findings and limitations.

PubMed

This research background explains the compound’s scientific relevance, but it is not a product endorsement. Clinical outcomes depend on the studied medicine, dose, population, monitoring and other trial conditions. Research literature should not be used to imply that a product with unverified identity or quality has demonstrated the same outcomes.

Quality and trust

Peptide Depot should publish only product details that can be substantiated. Before listing Mazdutide 10mg, confirm the supplier and manufacturer, exact presentation, labelled quantity, batch traceability, applicable storage instructions and any available analytical documentation.

If a CoA is supplied, identify the batch it covers and describe the tests actually reported. Do not claim independent testing, a specific purity percentage, sterile manufacture, Good Manufacturing Practice (GMP) compliance or pharmaceutical-grade quality unless suitable evidence supports the particular claim.

Customers should also be able to find clear information about the seller, contact options, checkout security, shipping terms and any applicable return policy. These are separate from the chemical quality and legal status of the product and should not be presented as proof of either.

Buying with confidence

Before making a decision about any peptide-labelled product, check that the product identity, quantity, documentation and intended purpose are clearly stated. Ask the supplier to clarify missing specifications rather than relying on assumptions based on the product name or images.

UK customers should also distinguish between a research-labelled item and a medicine legally authorised for supply. The MHRA’s guidance on medicines licensing and applications explains the UK regulatory framework. A “research use only” statement does not automatically make a product exempt from medicines law or make its supply lawful.

GOV.UK

+1

Important research-use notice

Where the specific product is legitimately designated for research purposes only, it must be labelled and described accordingly and must not be marketed as a treatment for human use. This notice does not itself establish lawful supply or remove applicable regulatory obligations. Do not publish this listing as an ordinary consumer medicine or imply UK authorisation unless the exact product’s regulatory status has been verified.

Publication condition: Confirm the product’s legal classification and permitted UK supply route before enabling purchase. The brand, format, packaging, purity, storage and documentation details also need confirmation.